NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
This is a contract result notice, not an open opportunity. Details from the official award data.
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 Offer reference number: CM/PHS/25/5728 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
Potential periods of call-offs under the framework agreement: CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National) 01/12/2025 to 31/05/2027 (18 months) CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg: NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months) SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months) MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months) LNW: (London) 01/12/2025 to 31/05/2027 (18 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England.
To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
What the notice asks for
Published By: Medicines Procurement and Supply Chain
Published By: Medicines Procurement and Supply Chain.
Sentences from the notice that state an obligation, surfaced automatically and shown in the order they appear. Not an exhaustive list — always confirm against the tender documents.
What this notice demands of you
1 named, none in explicit obligation language. Each one is quoted from the notice.
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.
Matched against the notice text, so this is a floor — the tender pack will demand things the notice never mentions. “Says must” means the quoted sentence itself used obligation language; anything ambiguous is left as a mention.
Make the case to bid
Reveal who to approach at NHS England, and generate a go-to-market strategy from their news, accounts and people.
Free to start. Named contacts come from published notices; the strategy is generated from the buyer’s news, accounts and people.
- OCID
- ocds-h6vhtk-055064
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 062482-2025
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
NHS England’s tender network